Company Snapshot

Investment Thesis

Pfizer is transitioning from pandemic-era revenue highs toward a diversified portfolio anchored in oncology, vaccines, and specialty care. Cost rationalization, business development, and filed launches aim to offset patent expirations and declining COVID demand.

  • Pipeline Execution: Management targets $20B+ in new launch revenue by 2030, led by oncology and RSV assets.
  • Cost Reset: $4B efficiency program realigns expenses with post-COVID volume.
  • Balance Sheet: Leverage improved following the Seagen acquisition financing, preserving investment grade.

Revenue Mix

Vaccines 35% — Prevnar, RSV, COVID franchise
Oncology 20% — Ibrance, Xtandi, Seagen assets
Internal Medicine 25% — Eliquis, Vyndaqel
Rare Disease & Other 20% — Genotropin, Gene therapies

Mix reflects Pfizer 2024 guidance midpoint.

Recent Performance

MTD +0.32%
QTD -9.11%
YTD -7.07%
5Y -30.06%

Shares lag peers given COVID revenue declines and near-term earnings pressure. Investors focus on launch execution, integration of Seagen’s oncology portfolio, and capital allocation discipline.

Strategic Insights

Oncology Focus

Seagen adds antibody-drug conjugate expertise, creating a leading franchise in solid tumors.

Vaccine Innovation

mRNA and protein-based platforms expand beyond COVID into influenza and shingles opportunities.

Capital Returns

High dividend yield and opportunistic buybacks offer support while management pursues bolt-on deals.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...